Advancements in Neoadjuvant Therapy for Renal Cell Carcinoma and Prostate Cancer: A Promising Outlook for Improved Patient Outcomes

Advancements in Neoadjuvant Therapy for Renal Cell Carcinoma and Prostate Cancer: A Promising Outlook for Improved Patient Outcomes

Introduction:
The fields of oncology and urology have witnessed significant advancements in the management of renal cell carcinoma (RCC) and prostate cancer. Two recent studies, namely "ASCO GU 2020: Challenging Clinical Scenarios in the Management of Renal Cell Carcinoma: Neoadjuvant Therapy for Localized RCC" and "AUA 2020: Apalutamide for Metastatic Castration-Sensitive Prostate Cancer in TITAN: Prognostic Importance of Prostate-Specific Antigen Responses," shed light on the potential of neoadjuvant therapy in improving patient outcomes. This article will explore the common points between these studies and delve into the theoretical benefits of neoadjuvant systemic therapy in localized RCC and metastatic castration-sensitive prostate cancer.

Neoadjuvant Therapy in Renal Cell Carcinoma:
The ASCO GU 2020 study discusses a prospective clinical trial of axitinib, an oral tyrosine kinase inhibitor, in RCC patients with tumor thrombus. The trial, registered as NCT03494816, aims to evaluate the efficacy of neoadjuvant axitinib in reducing tumor size. Preliminary results from a second study involving neoadjuvant axitinib in 18 patients showed a median reduction of 17% in the primary tumor. Furthermore, 25% of patients experienced a partial response. Another phase 2 trial with neoadjuvant axitinib in 24 patients demonstrated a median reduction of 28% in the primary tumor, with 46% of patients exhibiting a partial response based on RECIST criteria.

These findings highlight the potential of neoadjuvant systemic therapy as a viable option for localized RCC. While it is not currently considered a standard of care, the theoretical benefits of neoadjuvant therapy cannot be ignored. By reducing tumor size before surgery, neoadjuvant therapy may facilitate complete tumor resection, improve surgical outcomes, and potentially increase the chances of cure. Additionally, neoadjuvant therapy could serve as a valuable tool for assessing treatment response and identifying patients who may benefit from adjuvant therapy post-surgery.

Neoadjuvant Therapy in Metastatic Castration-Sensitive Prostate Cancer:
The AUA 2020 study focuses on the use of apalutamide, an androgen receptor inhibitor, in the treatment of metastatic castration-sensitive prostate cancer. The study evaluates the depth of prostate-specific antigen (PSA) response following treatment with apalutamide. Patients were categorized based on their PSA decline from baseline, with subgroups including <=0.2 ng/ml decline, <50% decline, >=50-90% decline, and >=90% decline.

Understanding the depth of PSA response is crucial as it provides prognostic information and aids in treatment decision-making. The study found that patients with a >=90% decline in PSA levels had a more favorable prognosis compared to those with lesser declines. This underscores the importance of achieving a deep PSA response in metastatic castration-sensitive prostate cancer patients, as it may correlate with improved survival outcomes.

Drawing Connections:
Despite focusing on different cancer types, these two studies share a common thread - the evaluation of neoadjuvant therapy and its impact on treatment outcomes. By incorporating neoadjuvant therapy into the treatment plan, both RCC and prostate cancer patients may experience significant benefits.

Neoadjuvant therapy offers the possibility of downsizing primary tumors, reducing tumor burden, and potentially increasing the chances of complete surgical resection. This, in turn, may improve the effectiveness of subsequent treatments, such as adjuvant therapy, and ultimately enhance patient outcomes. Additionally, the depth of treatment response, as measured by PSA decline, serves as a valuable prognostic indicator in both RCC and prostate cancer, highlighting the importance of monitoring response to neoadjuvant therapy.

Actionable Advice:

1. Incorporate neoadjuvant therapy into the treatment approach: For RCC patients with tumor thrombus or locally advanced non-metastatic clear cell RCC, consider neoadjuvant therapy with axitinib to potentially reduce tumor size and improve surgical outcomes.

2. Monitor PSA response in metastatic castration-sensitive prostate cancer: Utilize regular PSA measurements to evaluate treatment response in patients receiving apalutamide or similar therapies. Strive for a deep PSA response, as it may correlate with improved prognosis.

3. Consider the potential benefits of adjuvant therapy: For patients who undergo neoadjuvant therapy and subsequently undergo surgery, assess the need for adjuvant therapy based on tumor response and individual risk factors.

Conclusion:
The studies discussed in this article highlight the promising potential of neoadjuvant therapy in the management of renal cell carcinoma and metastatic castration-sensitive prostate cancer. By incorporating neoadjuvant therapy into treatment plans, healthcare professionals have the opportunity to improve patient outcomes, enhance surgical success rates, and potentially increase the chances of long-term survival. By monitoring treatment response, both through tumor size reduction and PSA decline, clinicians can make informed decisions regarding adjuvant therapy and tailor treatment approaches to individual patients. As research in these areas continues to evolve, the future of neoadjuvant therapy appears bright, offering hope for improved outcomes in patients with RCC and prostate cancer.